Improving Lives through

Cell and Gene Therapy

Cure Genetics
Committed to the development of gene and cell therapy for oncology and genetic diseases
Cure Genetics is a clinical stage biotechnology company focusing on development of cutting-edge gene and cell therapies through its comprehensive proprietary research platforms. We apply these advanced technology platforms for the development of innovative cancer and genetic diseases therapies in order to satisfy unmet medical needs.

Explore

Focus
Cure Genetics focus on the cell and gene therapy for solid tumors and genetic diseases.

Explore

Our Science
Immune cell therapy has revolutionized treatment for cancer patients. However, it still faces myriad challenges in solid tumors. One of the major challenges is the presence of tumor microenvironment (TME) in solid tumors, which can suppress functions of immune cells.

Cure Genetics has developed three unique technology platforms, including gene editing, viral vector delivering system, and molecular reconstruction. Based on the above platforms, it has established immune cell therapy pipeline for solid tumors and innovative AAV serotype products for genetic diseases.

Explore

News

More

Robert R. Ruffolo Joins CureGenetics's Scientific Advisory Board
2022.04.01
Robert R. Ruffolo Joins CureGenetics's Scientific Advisory Board

In April 2022, Suzhou, China, Cure Genetics, a biotechnology company focusing on development of cutting-edge gene and cell therapies, announced that Dr. Robert R. Ruffolo has joined its Scientific Advisory Board (SAB). Where he will provide scientific guidance to Cure Genetics technology platform and R&D pipeline, as well as assisting the Company’s global partnership effort.

Cure Genetics Completed $60 Million Series B Financing
2022.01.05
Cure Genetics Completed $60 Million Series B Financing

On January 5, 2022, Cure Genetics Biotechnology Co., Ltd. (hereinafter referred to as "CureGenetics") announced the completion of a US$60 million Series B financing. This round of financing was led by strategic investor Advantech Capital, followed by Oriza Holdings, BOCG and Qiming Venture Partners, with China Renaissance acting as the exclusive financial advisor.

Genevide, an incubation project of Cure Genetics, completed an angel round financing of RMB 50 million
2022.01.14
Genevide, an incubation project of Cure Genetics, completed an angel round financing of RMB 50 million

Recently, Genevide, an independent incubation company from Cure Genetics’s former molecular diagnostics business, announced the completion of a RMB 50 million angel round of financing led by Bioventure, co-invested by Qiming Ventures. Dr. Qiushi Li, former co-founder and COO of Cure Genetics, is named the co-founder and CEO of Genevide. “Genevide has built an Enzymes-mediated Duplex Exponential Amplification (EmDEATM) nPOCT technology platform with independent intellectual property portfolio using an innovative molecular enzyme cycle screening system based on enzyme characterization methods. We have built 4000m2 R&D, enzyme raw material manufacturing and IVD GMP manufacturing center in order to quickly promote the registration filings of our core products. “ Dr. Qiushi Li, Co-Founder and CEO of Genevide said.

Boehringer Ingelheim and Cure Genetics Collaborate to Develop Novel AAV Vectors for Next Generation Liver Targeted Gene Therapy
2021.01.18
Boehringer Ingelheim and Cure Genetics Collaborate to Develop Novel AAV Vectors for Next Generation Liver Targeted Gene Therapy

Boehringer Ingelheim (BI) and Cure Genetics Co., Ltd (Cure Genetics) today announced a collaboration to develop novel adeno-associated viral (AAV) vectors for next-generation gene therapy through Cure Genetics's proprietary VELPTM platform. This new collaboration combines BI's experience in disease mechanism research and gene therapy development with Cure Genetics's expertise in viral library construction and high-efficient in vivo AAV screening, providing patients with potentially safer and more efficient novel AAV serotypes.